A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.

Stopeck, Alison T

A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. [electronic resource] - Leukemia & lymphoma May 2009 - 728-35 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1029-2403

10.1080/10428190902856808 doi


Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors--administration & dosage
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Humanized
Bevacizumab
Biomarkers--analysis
Disease-Free Survival
Humans
Lymphoma, Large B-Cell, Diffuse--drug therapy
Lymphoma, Mantle-Cell--drug therapy
Lymphoma, Non-Hodgkin--drug therapy
Male
Middle Aged
Receptors, Vascular Endothelial Growth Factor--analysis
Salvage Therapy--methods
Southwestern United States
Vascular Cell Adhesion Molecule-1--blood